Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775931 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplantation For Severe Osteopetrosis
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00775931 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants.
The verdict
NCT00775931, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this research is to explore what we believe may be a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality. Prior multi-institutional data in past studies found that approximately 30% of Osteopetrosis patients do not engraft. Therefore, in this study, we utilize a reduced intensity design of pre-transplant drugs to try to make transplants safer for this disease, as well as to provide a second infusion of stem cells in patients with matched related or unrelated donors.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- PROCEDURE umbilical cord blood transplantation
- DRUG Campath-1H
- RADIATION Total Lymphoid Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775931
The ClinicalTrials.gov registry entry for NCT00775931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00775931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00775931 about?
NCT00775931 is a clinical study titled "Allogeneic Transplantation For Severe Osteopetrosis". The purpose of this research is to explore what we believe may be a safer and more effective means of performing stem cell transplantation in patients with Osteopetrosis, using chemotherapy and radiation designed to bring about engraftment and lessen transplant mortality. Prior multi-institutional d...
What is the current status of trial NCT00775931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-08. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00775931?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), umbilical cord blood transplantation (PROCEDURE), Campath-1H (DRUG), Total Lymphoid Irradiation (RADIATION).
Who is sponsoring clinical trial NCT00775931?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.